Tirzepatide, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, represents a novel therapeutic option for both glycemic control and ...
Summit Research and Prime Peptides after an investigation by the FDA found they were selling semaglutide, tirzepatide and/or retatrutide products for human use despite marketing the drugs for ...
For example, in a study of tirzepatide, participants lost approximately 21% of their body weight over 16 months on the highest dose. Newer peptides are being developed to minimize common side ...
Summit Research and Prime Peptides, four online companies it said were selling unapproved GLP-1 drugs, including semaglutide and tirzepatide. Semaglutide is known for its use in Wegovy and Ozempic ...